Increasing incidence of trauma cases and rising adoption of sedentary lifestyle are attributed to propels the growth of the global thrombus treatment market at a CAGR of 6.84% during the forecast period 2022 to 2030

Market Research Future (MRFR) has published a cooked research report on the “global thrombus treatment market” that contains the information from 2022 to 2030.

Global Thrombus Treatment Market Highlights

The global thrombus treatment market is accounted to register a CAGR of 6.84% during the forecast period (2022-2030) and is estimated to reach USD 69.94 billion by 2030.

A thrombus is a type of blood clot that forms inside blood vessels and restricts blood flow. Venous thrombosis and arterial thrombosis are the two types of thrombus. Thrombus can form in either the arteries or the veins. In contrast to arterial thrombosis, which affects the blood supply and damages the tissue served by that artery, venous thrombosis (also known as DVT) causes a blood clot to form in the affected area of the body. Thrombus treatment options for thrombus include surgery, antiplatelet, anticoagulant, and thrombolytic medications. The most common and effective thrombosis treatments are anticoagulants. These assist in halting the development of new blood clots.

The global thrombus treatment market is expected to be driven by increasing incidence of trauma cases and rising adoption of sedentary lifestyle. However, the global thrombus treatment market is likely to be restrained by the risks associated with thrombosis medications. On the other hand, new product launches and approvals are expected to create lucrative growth opportunities for players operating in the global thrombus treatment market.

MRFR recognizes the following companies as the key players in the global thrombus treatment market— Teva Pharmaceutical Industries Ltd. (Israel), AngioDynamics Inc. (US), Bristol-Myers Squibb Company (US), Pfizer Inc. (US), Johnson & Johnson Services Inc. (US), Sanofi S.A. (France), Daiichi Sankyo Company, Limited (Tokyo), Boehringer Ingelheim International GmbH (Germany), Aspen Pharmacare Holdings Limited (US), Bayer AG (Germany) and others.

Segment Analysis

The global thrombus treatment market has been bifurcated, based on type and treatment.

On the basis of type, the market is segmented into atrial thrombus and venous thrombus. The venous thrombus segment held the largest market in 2021 with a market share 58.58%.

Based of treatment, the market has been segmented into medical therapy, surgery, and others. The medical therapy held the largest market in 2021.  

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Thrombus Treatment Market Research Report

Regional Analysis

The global thrombus treatment market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe thrombus treatment market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The thrombus treatment market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The rest of the world thrombus treatment market comprises of Middle East, Africa, and Latin America.

The presence of key players in North America region such as Johnson & Johnson (US), Bristol-Myers Squibb (US), and others propel the growth of the thrombus treatment market in region. Moreover, an increasing number of companies are partnering and investing heavily in research and development to gain a significant market share.

Furthermore, the rise in the number of initiatives undertaken by various public and private organizations in the form of acquisitions, collaborations, regulatory approvals, and investments is aiding to Europe region’s growth. For instance, in September 2020, Mylan N.V. (US) announced the acquisition of Aspen Pharmacare Holdings Limited's (South Africa) thrombosis business in Europe for USD 636.9 million.

Likewise, a growing number of inveterate diseases such as diabetes boosts the Asia-Pacific market's growth. According to the World Health Organization (WHO) in 2021, 422 million people are suffering from diabetes, and the number has been rising more rapidly in low-and middle-income countries than in high-income countries. Additionally, there has been a rise in the quality of research in Asia-Pacific, which is coupled with increasing research opportunities driven by rapid economic growth in Asia-Pacific.

In addition, the rise in the prevalence of atrial fibrillation and initiatives undertaken by various public and private organizations to provide improved access to diabetes mellitus care, and healthcare facilities are anticipated to drive the market growth in the coming years.

Key Findings of the Study

• The global thrombus treatment market is expected to reach USD 69.94 billion by 2030 at a CAGR of 6.84% during the forecast period.


• The Europe region held the second largest market share of the global market, owing to the increase in R&D and strategic initiatives.


• Based on treatment, the medical therapy segment held the largest market in 2021, with a market share of 89.15%.